Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, ...
GB News on MSN

Prostate cancer slowed by popular supplement and vegetable-rich diet in breakthrough study

Taking probiotic supplements alongside a diet abundant in vegetables may offer strong protection against low-risk prostate ...

Broccoli and pomegranate could slow spread of prostate cancer

Probiotics and broccoli could help to slow the spread of prostate cancer, research suggests. Broccoli, turmeric, pomegranate, ...

Fibre-rich diet and probiotics may slow some prostate cancer: study

Eating lots of vegetables and taking probiotic supplements could help to slow the growth of low-risk prostate cancer, a study ...

Study confirms high cost effectiveness of prostate cancer screening

A research team from the Department of Surgery and the Department of Medicine, School of Clinical Medicine, LKS Faculty of ...
NHS England

Menopause and prostate conditions prioritised for NHS’s new online hospital

Menopause and prostate problems will be among the priorities for the NHS’s revolutionary new online hospital when it launches next year. The NHS has selected nine common conditions which will be the ...

Switching from finasteride to dutasteride for hair loss? Here’s what to expect

Research supports that both finasteride and dutasteride help treat hair loss, particularly when caused by androgenetic ...
thesun.ng on MSN

Prostate cancer: Silent killer of black men

By Oluseye OjoIn Nigeria, prostate cancer is a silent killer of men, claiming approximately 31 lives daily.In 2022, records showed that the country recorded 18,019 new cases, resulting in 11,443 ...
WPRI 12

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs ...

"There remains an urgent need for novel therapies for patients with BRCA2-mutated mCSPC, who face significantly faster disease progression and often shorter survival compared to those without the ...
Finanznachrichten

Johnson & Johnson: U.S. FDA approves AKEEGA as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease ...

Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...